Effect Of Botulinum Toxin Type-A In Spasticity And Functional Outcome Of Upper Limbs In Cerebral Palsy
ConclusionI.m. BTX-A injected using anatomical landmarks had significant improvement in both clinical and functional outcome measures. We noticed significant improvement in MACS and COPM at 6 months despite return of local spasticity. It is safe and effective for spasticity of upper limbs in cerebral palsy and capable of improving function without major side effects. MACS & COPM are easy to use, less time consuming & easily adjusted to local needs. Randomized control trials with long follow up are required in future with special focus on dosing and timing, scoring system for functional outcome as per regional needs...
Source: Journal of Clinical Orthopaedics and Trauma - January 9, 2020 Category: Orthopaedics Source Type: research

A prospective study investigating gross motor function of children with cerebral palsy and GMFCS level II after long-term Botulinum toxin type A use
The aim of this study is to contribute to the knowledge base on the long-term outcomes of evidence-based medical interventions used to improve gross motor function in children and adolescents with Cerebral Palsy. (Source: BMC Pediatrics)
Source: BMC Pediatrics - January 6, 2020 Category: Pediatrics Authors: Jane Valentine, Sue-Anne Davidson, Natasha Bear, Eve Blair, Lisa Paterson, Roslyn Ward, David Forbes and Catherine Elliott Tags: Research article Source Type: research

Five-year follow-up of patients treated with intra-dermal botulinum toxin for axillary hyperhidrosis
AbstractBackgroundAxillary hyperhidrosis is a common complaint affecting 5% of the general population. It can significantly impact quality of life (QOL) and may be extremely debilitating. Administration of intra-dermal botulinum toxin type-A (Botox) has been proven to be effective in managing axillary hyperhidrosis; however, to date, no long-term data has assessed its efficacy.AimWe aim to assess long-term (> 5 years) QOL outcomes in this patient cohort.MethodsIn this single-centre series, all patients attending for axillary botox, with five or more years of follow-up, were prospectively included. QOL was assessed in al...
Source: Irish Journal of Medical Science - January 3, 2020 Category: General Medicine Source Type: research

Neurotoxin Impurities: A Review of Threats to Efficacy
Source: Plastic and Reconstructive Surgery Global Open - January 1, 2020 Category: Cosmetic Surgery Tags: Special Topic Source Type: research

The efficacy of intra dermal injections of botulinum toxin in management of enlarged facial pores and seborrhea: A split face controlled study.
Authors: Sayed KS, Hegazy R, Gawdat HI, Mounir R, Ahmed MM, Nouredin Mohammed F, Allam R, Fahim A Abstract Background: Enlarged facial pores are becoming a matter of cosmetic concern. Injections of (botulinum toxin type A) have an increasing popularity among cosmetic procedures.Objective: To determine the efficacy and safety of intradermal injection of botulinum toxin in treatment of excess sebum secretion and enlarged facial pores .Materials and methods: This split face controlled pilot study was conducted on 20 patients with enlarged facial pores and seborrhea. One cheek was treated by intradermal injection of bo...
Source: Journal of Dermatological Treatment - December 24, 2019 Category: Dermatology Tags: J Dermatolog Treat Source Type: research

The Use of Botulinum Toxin Type A in the Healing of Thyroidectomy Wounds: A Randomized, Prospective, Placebo-Controlled Study
No abstract available (Source: Plastic and Reconstructive Surgery)
Source: Plastic and Reconstructive Surgery - December 24, 2019 Category: Cosmetic Surgery Tags: Letters Source Type: research

Appropriate Timing of Early Postoperative Botulinum Toxin Type A Injection for Thyroidectomy Scar Management: A Split-Scar Study: Correction
No abstract available (Source: Plastic and Reconstructive Surgery)
Source: Plastic and Reconstructive Surgery - December 24, 2019 Category: Cosmetic Surgery Tags: Corrections Source Type: research

DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2)
Background: DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A formulation in clinical development. A phase 2 dose-ranging study identified an optimal dose and demonstrated efficacy with a median duration of 24 weeks. Methods: In two phase 3, multicenter, randomized, double-blind, placebo-controlled studies (SAKURA 1 and SAKURA 2), subjects with moderate or severe glabellar lines at maximum frown were assigned randomly to receive placebo or 40 U of DAXI. Glabellar lines were evaluated at least every 4 weeks for at least 24 weeks until severity returned to baseline (≤36 weeks). Results: Ov...
Source: Plastic and Reconstructive Surgery - December 24, 2019 Category: Cosmetic Surgery Tags: Cosmetic: Original Articles Source Type: research

Botulinum Toxin A Salvage of Ischemic Hand Trauma
Summary: Posttraumatic hand injuries from crush injury, infusion, or iatrogenic vascular cannulation can cause ischemic finger damage that can progress to necrosis and digital amputation. Botulinum toxin type A (Botox) improves blood flow in chronic vasospastic disorders of the hand. Botox’s efficacy in salvaging ischemic loss in digits in acute traumatic and iatrogenic injury has not been previously reported. From February of 2015 to December of 2016, 11 patients at a Level I trauma center (West Virginia University) presented to the hand surgery service with early ischemic injury and vascular compromise to hand an...
Source: Plastic and Reconstructive Surgery - December 24, 2019 Category: Cosmetic Surgery Tags: Hand/Peripheral Nerve: Ideas and Innovations Source Type: research

The Efficacy of Drug Injection in the Treatment of Pathological Scar: A Network Meta-analysis
ConclusionIn the injection treatment of pathological scar, we recommend the combined injection of two drugs, especially botulinum toxin type A combined with corticosteroids. The effective treatment of botulinum toxin type A combined with corticosteroids in the treatment of pathological scar is as follows: Patients were treated once monthly with intralesional injection of TAC (0.1  ml/cm3) mixed with botulinum toxin type A (2.5  IU/cm3) for a total of 3 treatments. However, there are still limitations in this network meta-analysis, and its conclusion still needs to be further confirmed by more randomized controlle...
Source: Aesthetic Plastic Surgery - December 18, 2019 Category: Cosmetic Surgery Source Type: research

Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine
AbstractMore than 0.6 million people suffer from disabling migraines in Greece causing a dramatic work loss, but only a small proportion of migraineurs attend headache centres, most of them being treated by non-experts. On behalf of the Hellenic Headache Society, we report here a consensus on the diagnosis and treatment of adult migraine that is based on the recent guidelines of the European Headache Federation, on the principles of Good Clinical Practice and on the Greek regulatory affairs. The purposes are three-fold: (1) to increase awareness for migraine in Greece; (2) to support Greek practitioners who are treating mi...
Source: The Journal of Headache and Pain - December 13, 2019 Category: Neurology Source Type: research

Intramural Injection of Botulinum Toxin A in Surgical Treatment of a Long Gap Esophageal Atresia —Rat Model
Conclusion We found that BTX-A exerts a positive effect on stretch characteristics of esophageal tissue in rats at 2 U/kg via four-injection delivery and 24-hour waiting period. This study suggests that BTX-A might improve anastomotic healing. [...] Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text (Source: European Journal of Pediatric Surgery)
Source: European Journal of Pediatric Surgery - December 13, 2019 Category: Surgery Authors: Pike, Ashton Hideki Zvara, Peter Antulov, Marijana Rincic Schr øder, Henrik Daa Hejboel, Eva Kildall Rasmussen, Lars Qvist, Niels Elleb æk, Mark Bremholm Tags: Original Article Source Type: research

Botulinum toxin type a for first bite syndrome - a case report
Publication date: December 2019Source: British Journal of Oral and Maxillofacial Surgery, Volume 57, Issue 10Author(s): Rachael Harlow, Lachlan Carter (Source: British Journal of Oral and Maxillofacial Surgery)
Source: British Journal of Oral and Maxillofacial Surgery - December 12, 2019 Category: ENT & OMF Source Type: research

Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment
ConclusionTear abnormalities seen in BEB correspond to short BUT-type dry eye (DE), subclassified into decreased wettability DE in view of FBUPs. (Source: Japanese Journal of Ophthalmology)
Source: Japanese Journal of Ophthalmology - December 10, 2019 Category: Opthalmology Source Type: research

Treatment of symptomatic epiblepharon with Botulinum toxin type A in patients under 2years of age.
CONCLUSIONS: The present study provides evidence that a pretarsal BoNT-A injection is an effective and safe treatment for the correction of symptomatic epiblepharon in patients younger than 2 years of age. PMID: 31806264 [PubMed - as supplied by publisher] (Source: Archivos de la Sociedad Espanola de Oftalmologia)
Source: Archivos de la Sociedad Espanola de Oftalmologia - December 8, 2019 Category: Opthalmology Tags: Arch Soc Esp Oftalmol Source Type: research

Management of Functional Esophagogastric Junction Outflow Obstruction: A Systematic Review
Conclusions: There are a variety of management strategies available for fEGJOO and some patients may not require any intervention. However, among 4 potential approaches aimed at disrupting lower esophageal sphincter hypertonicity, the largest existing evidence base supports either a therapeutic challenge of Botox injection or watchful waiting. Ultimately, these data indicate the need for further study with controlled trials to identify a definitive approach. (Source: Journal of Clinical Gastroenterology)
Source: Journal of Clinical Gastroenterology - December 7, 2019 Category: Gastroenterology Tags: ALIMENTARY TRACT: Original Articles Source Type: research

OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females
This 24-week double-blind placebo-controlled multicenter randomized phase 2 trial evaluated efficacy and safety of onabotulinumtoxinA (onabotA; BOTOX) vs. placebo for major depressive disorder (MDD) [NCT02116361]. Primary endpoint was the change in Montgomery-Åsberg Depression Rating Scale (MADRS); secondary endpoints were Clinical Global Impressions-Severity and 17-item Hamilton Depression Rating Scale at week 6. A total of 255 adult females were treated. OnabotA 30 U approached significance compared to placebo on MADRS (mixed-effect model repeated measures least-squares mean difference: −3.7; P = 0.053) and r...
Source: International Clinical Psychopharmacology - December 3, 2019 Category: Psychiatry Tags: Original Articles Source Type: research

Gastric Per Oral Pyloromyotomy for Post-Vagotomy-Induced Gastroparesis Following Esophagectomy
ConclusionsGPOP status post-esophagectomy presented multiple challenges: difficulty maintaining field of view and insufflation, establishing tension and counter tension for the mucosotomy, and a limited working space. With care and patience, endoscopists trained to perform POEM may apply their skillset to help a large population of patients suffering with post-esophagectomy gastroparesis. (Source: Journal of Gastrointestinal Surgery)
Source: Journal of Gastrointestinal Surgery - December 2, 2019 Category: Surgery Source Type: research

Is BOTOX ® able to improve your Pain and Quality of life? Can this be measured?
Introduction Aetiology of TMD is multifactorial; symptoms may be of intra articular, myofascial or mixed aetiology leading to varied management. BOTOX ® may benefit symptoms of myofascial pain although a systematic review of RCT's was inconclusive. Currently all our TMD patients have psychological assessment using IMPARTS (Integrating mental and physical: research training and services). A package of questionnaire's scoring pain (BPI), anxiety (G AD-7), depression (PHQ9) and oral function (OHIP-14) is given to patients suffering from TMD. (Source: The British Journal of Oral and Maxillofacial Surgery)
Source: The British Journal of Oral and Maxillofacial Surgery - December 1, 2019 Category: ENT & OMF Authors: Hanna Strang, Salim Miskry, Kathleen Fan Tags: P210 Source Type: research

Botulinum toxin type a for first bite syndrome - a case report
Introduction: First bite syndrome (FBS) – a condition first described in 1986 by Haubrich, is a condition typified as intense, often neuralgic pain in the parotid gland on the first bite of food, that decreases in severity with each further bite1-4. The condition most commonly occurs following surgery to the parotid gland, within the pa rapharyngeal or infratemporal space. Adenervation injury can result in hypersensitivity of the sympathetic fibres that supply the myoepithelial cells of the parotid4. (Source: The British Journal of Oral and Maxillofacial Surgery)
Source: The British Journal of Oral and Maxillofacial Surgery - December 1, 2019 Category: ENT & OMF Authors: Rachael Harlow, Lachlan Carter Tags: P194 Source Type: research

Anti-cancer Potential of Captopril and Botulinum Toxin Type-A and Associated p53 Gene Apototic ...
Mutational inactivation of p53 is a key player in the development of human cancer. Thus, retrieving the tumor suppressor activity of p53 gene is considered a novel strategy in cancer therapy. Current study aimed to investigate the anti-cancer potentials of botulinum toxin type-A (BTX-A) and captopril as a trial to shed light on effective anti-cancer therapy with lower side effects. Cytotoxic effect of captopril and BTX-A was determined using MTT assay against colon (HCT116) and prostate cancer (DU145) cells compared to their effect on normal vero cells. Anti-proliferation assay and anti-metastatic effect were carried out u...
Source: Iranian Journal of Pharmaceutical Research - November 30, 2019 Category: Drugs & Pharmacology Source Type: research

DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase  3 studies (SAKURA 1 and SAKURA 2)
DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A in clinical development. Phase 2 data have shown it offers a more prolonged duration of response than onabotulinumtoxinA. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - November 29, 2019 Category: Dermatology Authors: Vince Bertucci, Nowell Solish, Joely Kaufman-Janette, Steve Yoelin, Ava Shamban, Joel Schlessinger, Daniel Snyder, Conor Gallagher, Yan Liu, Gill Shears, Roman G. Rubio Tags: Original article Source Type: research

Interrater Reliability of the Modified Ashworth Scale with Standardized Movement Speeds: A Pilot Study.
Conclusion: Using consistent movement velocity, novice evaluators were able to score spasticity with reasonable interrater reliability when assessing the wrist flexors but not the ankle plantar flexors. PMID: 31762545 [PubMed] (Source: Physiotherapy Canada)
Source: Physiotherapy Canada - November 27, 2019 Category: Physiotherapy Authors: Zurawski E, Behm K, Dunlap C, Koo J, Ismail F, Boulias C, Reid S, Phadke CP Tags: Physiother Can Source Type: research

The Use of Botulinum Toxin Type A in the Healing of Thyroidectomy Wounds: A Randomized, Prospective, Placebo-Controlled Study
No abstract available (Source: Plastic and Reconstructive Surgery)
Source: Plastic and Reconstructive Surgery - November 27, 2019 Category: Cosmetic Surgery Tags: Letters Source Type: research

Visualizing the Pharmacologic Preconditioning Effect of Botulinum Toxin Type A by Infrared Thermography in a Rat Pedicled Perforator Island Flap Model
Conclusions: Botulinum toxin type A can convert choke anastomoses into true anastomoses, and its preconditioning effect cannot increase over time; it is appropriate to choose the timing point when the infrared thermal images show a continuous white band existing over flaps for flap transfer. (Source: Plastic and Reconstructive Surgery)
Source: Plastic and Reconstructive Surgery - November 27, 2019 Category: Cosmetic Surgery Tags: Experimental Source Type: research

Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity.
We report the case of a 33-year-old female who had been receiving regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotulinum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when ca...
Source: Acta Medica Portuguesa - November 25, 2019 Category: General Medicine Tags: Acta Med Port Source Type: research

Botulinum toxin type A injection-related suppurative granuloma: a case report
. (Source: Journal of Cosmetic and Laser Therapy)
Source: Journal of Cosmetic and Laser Therapy - November 12, 2019 Category: Laser Surgery Authors: Wilai Thanasarnaksorn Bheerathida Rattakul Saroj Suvanasuthi Nalinee Sutthipisal Source Type: research

Novelty in Inflammation and Immunomodulation in Migraine.
Abstract BACKGROUND: Migraine is a diffuse and disabling disease. Its pathophysiology is complex and involves both central and peripheral dysfunctions. OBJECTIVE: This review will discuss the pathogenesis of migraine from the origin of the neuro-inflammatory theory, to the modern pathophysiological model and the latest therapies. METHODS: PUBMED and EMBASE (up to May 2019) were searched for: migraine, inflammation, immunomodulation. An additional search was carried out from the bibliography of previous review articles. RESULTS: Migraine was thought to be mainly a vascular disorder, according to the ...
Source: Current Pharmaceutical Design - November 8, 2019 Category: Drugs & Pharmacology Authors: Cavestro C, Ferrero M, Mandrino S, Di Tavi M, Rota E Tags: Curr Pharm Des Source Type: research

Knee muscle atrophy is a risk factor for development of knee osteoarthritis in a rat model
ConclusionsQuadriceps muscle atrophy triggered the subchondral bone abnormal change and cartilage degeneration, which would be a risk factor for development of osteoarthritis. (Source: Journal of Orthopaedic Translation)
Source: Journal of Orthopaedic Translation - November 2, 2019 Category: Orthopaedics Source Type: research

Clinical effectiveness of ultrasound guided subacromial-subdeltoid bursa injection of botulinum toxin type A in hemiplegic shoulder pain: A retrospective cohort study
Hemiplegic shoulder pain (HSP), which occurs in most patients with hemiplegia, causes considerable distress and worsens outcomes in rehabilitation. Although they have received the treatments such as anti-inflammatory drugs or physical therapy, many of the individuals remain suffering from shoulder pain 6 months after acute stroke event. In this retrospective study, we evaluated the effectiveness of ultrasound guided subacromial-subdeltoid (SASD) bursa injections with botulinum toxin type A (BoNT/A) compared to steroids for refractory HSP. The data were collected retrospectively by reviewing the patient's medical records a...
Source: Medicine - November 1, 2019 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Botulinum toxin injection for internal anal sphincter achalasia after pull-through surgery in Hirschsprung disease
Botulinum toxin (Botox) was introduced for the management of internal anal sphincter (IAS) achalasia after a pull-through procedure in Hirschsprung disease (HD). We conducted a prospective evaluation of the efficacy and safety of this Botox treatment. Our study group included 15 patients with HD (median age, 4.8 years; range, 1.7–7.4 years) who experienced persistent constipation after pull-through surgery. Rectal biopsy and colon study were performed before Botox injection to exclude agangliosis. Intersphincteric Botox injections (dose, 4 IU/kg) were performed at 3 sites, (3, 6, and 9 o’clock) under general a...
Source: Medicine - November 1, 2019 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Trigger Site Inactivation for the Surgical Therapy of Occipital Migraine and Tension-type Headache: Our Experience and Review of the Literature
Source: Plastic and Reconstructive Surgery Global Open - November 1, 2019 Category: Cosmetic Surgery Tags: Special Topic Source Type: research

Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies
BACKGROUND PrabotulinumtoxinA is a 900-kDa botulinum toxin Type A produced by Clostridium botulinum. OBJECTIVE To investigate the efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines. MATERIALS AND METHODS Adult subjects (n = 330 in EV-001; n = 324 in EV-002) with moderate to severe glabellar lines at maximum frown on the 4-point Glabellar Line Scale (GLS; 0 = no lines, 1 = mild, 2 = moderate, and 3 = severe) were enrolled in 1 of 2 identical 150-day, double-blind, placebo-controlled, single-dose, Phase III studies. Subjects were randomized 3:1 to receive 20-U prabotulinumtoxinA or placebo...
Source: Dermatologic Surgery - October 24, 2019 Category: Dermatology Tags: Original Article Source Type: research

Temporalis Muscle Reduction Using Botulinum Toxin Type A for a Desirable Upper Face Circumference
Facial plast Surg 2019; 35: 559-560 DOI: 10.1055/s-0039-3399607 Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents  |  Full text (Source: Facial Plastic Surgery)
Source: Facial Plastic Surgery - October 22, 2019 Category: Cosmetic Surgery Authors: Jung, Gyu Sik Tags: Letter to the Editor Source Type: research

Comparison of Safety and Efficacy of Botox and Neuronox in the Management of Benign Essential Blepharospasm: A Split-face Study.
Authors: Sane S, Ali MJ, Naik MN Abstract PURPOSE: To compare the efficacy and safety of Botox and Neuronox in the management of benign essential blepharospasm (BEB). METHODS: We performed a triple-masked, randomized control study to compare Botox and Neuronox in 48 eyes of 24 patients with BEB. All 24 patients randomly received Botox or Neuronox in the periorbital region in a masked, randomized split-face manner, keeping the injection sites and doses uniform. The toxin preparation, injection, and clinical evaluations were done by three independent observers. Objective outcome measures included improvement in t...
Source: Korean Journal of Ophthalmology : KJO - October 17, 2019 Category: Opthalmology Tags: Korean J Ophthalmol Source Type: research

Correction to: How satisfied are cervical dystonia patients after 3  years of botulinum toxin type A treatment? Results from a prospective, long-term observational study
The article How satisfied are cervical dystonia patients after 3  years of botulinum toxin type A treatment? (Source: Journal of Neurology)
Source: Journal of Neurology - October 9, 2019 Category: Neurology Source Type: research

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy.
Abstract BACKGROUND: Cerebral palsy (CP) is the most common cause of physical disabilities in children in high-income countries. Spasticity is the most common motor disturbance in CP. Botulinum toxin type A (BoNT-A) is considered the first-line treatment for focal spasticity in people with CP. OBJECTIVES: To evaluate the effectiveness and safety of BoNT-A compared to other treatments used in the management of lower limb spasticity in children with CP. SEARCH METHODS: We searched CENTRAL, PubMed, four other databases, and two trial registers in October 2018. We also searched the reference lists of relevan...
Source: Cochrane Database of Systematic Reviews - October 8, 2019 Category: General Medicine Authors: Blumetti FC, Belloti JC, Tamaoki MJ, Pinto JA Tags: Cochrane Database Syst Rev Source Type: research

Botox Injection into the Lower Esophageal Sphincter Induces Hiatal Paralysis and Gastroesophageal Reflux.
CONCLUSION: ISIB, in addition to decreasing LES pressure, paralyzes the esophageal hiatus (crural diaphragm) and induces GER. PMID: 31589467 [PubMed - as supplied by publisher] (Source: American Journal of Physiology. Gastrointestinal and Liver Physiology)
Source: American Journal of Physiology. Gastrointestinal and Liver Physiology - October 7, 2019 Category: Physiology Authors: Kumar D, Zifan A, Mittal RK Tags: Am J Physiol Gastrointest Liver Physiol Source Type: research

Interventions for idiopathic toe walking.
CONCLUSIONS: The certainty of evidence from one study, which compared serial casting with serial casting with BTX for ITW in children, was too low for conclusions to be drawn. A further three studies reported outcomes relating to BTX, footwear, exercises, and different types of orthoses as interventions, however the outcome data were too limited to assess their effects. PMID: 31587271 [PubMed - as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - October 6, 2019 Category: General Medicine Authors: Caserta AJ, Pacey V, Fahey M, Gray K, Engelbert RH, Williams CM Tags: Cochrane Database Syst Rev Source Type: research

Extraoral Versus Intraoral Botulinum Toxin Type A Injection for Management of Temporomandibular Joint Disc Displacement With Reduction
Conclusion: The BTX-A injection into LPM is a simple technique that can be used with high success and low complication rate for treatment of ADDWR. The intraoral approach was superior to the extraoral concerning patient convenience and injection duration with no statistical difference regarding other clinical outcomes. (Source: Journal of Craniofacial Surgery)
Source: Journal of Craniofacial Surgery - October 1, 2019 Category: Surgery Tags: Clinical Studies Source Type: research

Botulinum Toxin Type A: Evaluation of Onset and Satisfaction
With the increasing interest in nonsurgical cosmetic procedures, this research study sought to evaluate the onset of Botulinum toxin Type A (BoNTA) between naive and non-naive consumers and its effect on satisfaction. This single-blinded research study consisted of 15 adults with scheduled appointments for neurotoxin treatment of undesired glabellar lines. Participants completed pretreatment FACE-Q scales. Both the participant and the researcher rated pretreated glabellar lines with the Merz 5-point scale. Daily photographs of the treated area were taken by the participant and submitted to the researcher over a secure elec...
Source: Plastic Surgical Nursing - October 1, 2019 Category: Nursing Tags: Departments: Previously Published Articles Source Type: research

A502 Endoscopic Gastric Botulinum as a Treatment for Obesity – Practical Aspects and Outcomes
Several small studies were published evaluating the effect of Endoscopic Gastric Botulinum Toxin type A (EGB) for the treatment of obesity giving conflicting results. Botulinum Toxin type A (BT-A) has a powerful inhibiting effect of long duration on the muscular contractions of smooth and striated muscles. This property has been used in the treatment of digestive illnesses characterized by muscular spasm, particularly achalasia and anal fissure (Source: Surgery for Obesity and Related Diseases)
Source: Surgery for Obesity and Related Diseases - October 1, 2019 Category: Surgery Authors: Enas Alawi Source Type: research

Appropriate Timing of Early Postoperative Botulinum Toxin Type A Injection for Thyroidectomy Scar Management: A Split-Scar Study
Conclusion: These results suggest that immediate postoperative BTxA injection is more effective for thyroidectomy scar management in terms of erythema, skin elasticity, and patient satisfaction. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II. (Source: Plastic and Reconstructive Surgery)
Source: Plastic and Reconstructive Surgery - September 27, 2019 Category: Cosmetic Surgery Tags: Reconstructive: Head and Neck: Original Articles Source Type: research

Early Postoperative Application of Botulinum Toxin Type A Prevents Hypertrophic Scarring after Epicanthoplasty: A Split-Face, Double-Blind, Randomized Trial
Conclusions: Early postoperative botulinum toxin type A injection in the medial canthal region efficiently reduces hypertrophic scarring and improves the outcome of epicanthoplasty. Therefore, botulinum toxin type A injection can be used as a routine method to prevent hypertrophic scarring and improve the outcome of epicanthoplasty. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II. (Source: Plastic and Reconstructive Surgery)
Source: Plastic and Reconstructive Surgery - September 27, 2019 Category: Cosmetic Surgery Tags: Cosmetic: Original Articles Source Type: research

[Long-term effectiveness of topical analgesics].
DISCUSSION: Despite the long duration of the disease, the most used off-label topical drugs L and B demonstrated a high primary response rate (in contrast to C), with most benefiting from long-term treatment. PMID: 31562537 [PubMed - as supplied by publisher] (Source: Schmerz)
Source: Schmerz - September 27, 2019 Category: Anesthesiology Authors: Kaisler M, Maier C, Kumowski N, Schwarzer A, Meyer-Frießem CH Tags: Schmerz Source Type: research

Ultrasonographic evaluation of the masseter muscle before and after botulinum toxin injection in patients with bruxism
ConclusionsCertain measurements of the masseter muscle with ultrasonography before and after botulinum type A injection in patients with bruxism may provide useful information in the follow-up process. Further research is essential, with more patients evaluated at different follow-up intervals. (Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology)
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - September 25, 2019 Category: ENT & OMF Source Type: research

Ultrasonographic evaluation of the masseter muscle before and after botulinum toxin injection in patients with bruxism
Bruxism is defined as a diurnal or nocturnal parafunctional activity of the masticatory muscles, with a prevalence of 20% and an impact of life quality. It is characterized by the compression and/or grinding of the teeth without purpose. In cases where conventional therapies are insufficient, botulinum toxin type A can be used as an alternative therapeutic treatment for patients who present masticatory muscle hyperfunction. (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - September 25, 2019 Category: ENT & OMF Authors: K. KAMBUROGLU, G. SONMEZ, R. NALCACI, E. YURTTUTAN, A.O. TUZUNEL Source Type: research

The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta ‐analysis of randomized controlled trials
ConclusionPooled data from our meta ‐analysis suggest that BTX‐A is efficacious and safe in treating TN and PNP. However, due to the limited sample size and heterogeneity, further larger and well‐designed RCTs are imperative to validate these findings. (Source: Brain and Behavior)
Source: Brain and Behavior - September 21, 2019 Category: Neurology Authors: Jiangshan Wei, Xiangyu Zhu, Guang Yang, Jun Shen, Peng Xie, Xiaohua Zuo, Lei Xia, Qiu Han, Ying Zhao Tags: ORIGINAL RESEARCH Source Type: research

Battling Neuropathic Scar Pain With Botulinum Toxin
We present a patient with refractory neuropathic pain in a normotrophic spread-scar treated with the injection of BTA. A 47-year-old Caucasian female with a history of invasive melanoma of the left upper arm presented with pain in her excision scar, which she described as a “pins and needles” sensation alternating with a dull, deep ache. She had previously tried topical lidocaine, topical and intralesional steroids, and oral gabapentin without improvement. We treated the patient with 50 U of onabotulinumtoxinA intradermally at 1-1.5 cm intervals within and immediately around the perimeter of the scar. At 1-wee...
Source: Journal of Drugs in Dermatology - September 18, 2019 Category: Dermatology Tags: J Drugs Dermatol Source Type: research